Datopotamab Deruxtecan EGFR-Mutated NSCLC: Approved FDA 3 Mins Read Introduction to Datopotamab Deruxtecan EGFR-Mutated NSCLC On June 23, 2025, the FDA approved Datopotamab Deruxtecan EGFR-Mutated NSCLC treatment, known as…
Datopotamab deruxtecan in advanced NSCLC TROPION-Lung01 Phase 3 Non-Small Cell Lung Cancer 2 Mins Read By. Aaron E. Lisberg, MD, Date. 11/14/2023 During ESMO 2023, Aaron E. Lisberg, MD, delivered a presentation on the results…
